阿帕鲁胺致药物性超敏综合征1例

Q4 Medicine

IJU Case Reports Pub Date : 2025-08-15 DOI:10.1002/iju5.70085

Yuki Tanaka, Yui Fujimura, Koya Morishita, Yuta Kashiwagi, Satoshi Katsuno, Tatsuya Nagai

{"title":"阿帕鲁胺致药物性超敏综合征1例","authors":"Yuki Tanaka, Yui Fujimura, Koya Morishita, Yuta Kashiwagi, Satoshi Katsuno, Tatsuya Nagai","doi":"10.1002/iju5.70085","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Apalutamide, an androgen receptor antagonist for prostate cancer, rarely causes drug-induced hypersensitivity syndrome (DIHS).</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 75-year-old male with prostate cancer and multiple bone metastases developed grade 2 rash and grade 3 liver dysfunction according to the Common Terminology Criteria for Adverse Events (CTCAE) 3 weeks after starting apalutamide with a GnRH antagonist, followed by a 3-day fever. Ten days later, symptoms worsened to grade 3 rash and grade 4 liver dysfunction. He met five diagnostic criteria for DIHS. Hormonal therapy was discontinued, and prednisolone plus intravenous immunoglobulin (IVIG) was administered. Fatigue resolved within 2 days, rash by day 6, and liver function improved to grade 2 by day 10. The patient is currently on abiraterone and a GnRH antagonist without adverse events.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This report highlights the importance of caution and regular blood tests when using apalutamide owing to the risk of DIHS.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 5","pages":"529-532"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70085","citationCount":"0","resultStr":"{\"title\":\"A Case of Drug-Induced Hypersensitivity Syndrome Caused by Apalutamide\",\"authors\":\"Yuki Tanaka, Yui Fujimura, Koya Morishita, Yuta Kashiwagi, Satoshi Katsuno, Tatsuya Nagai\",\"doi\":\"10.1002/iju5.70085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Apalutamide, an androgen receptor antagonist for prostate cancer, rarely causes drug-induced hypersensitivity syndrome (DIHS).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case Presentation</h3>\\n \\n <p>A 75-year-old male with prostate cancer and multiple bone metastases developed grade 2 rash and grade 3 liver dysfunction according to the Common Terminology Criteria for Adverse Events (CTCAE) 3 weeks after starting apalutamide with a GnRH antagonist, followed by a 3-day fever. Ten days later, symptoms worsened to grade 3 rash and grade 4 liver dysfunction. He met five diagnostic criteria for DIHS. Hormonal therapy was discontinued, and prednisolone plus intravenous immunoglobulin (IVIG) was administered. Fatigue resolved within 2 days, rash by day 6, and liver function improved to grade 2 by day 10. The patient is currently on abiraterone and a GnRH antagonist without adverse events.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This report highlights the importance of caution and regular blood tests when using apalutamide owing to the risk of DIHS.</p>\\n </section>\\n </div>\",\"PeriodicalId\":52909,\"journal\":{\"name\":\"IJU Case Reports\",\"volume\":\"8 5\",\"pages\":\"529-532\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70085\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJU Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70085\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

阿帕鲁胺是一种用于前列腺癌的雄激素受体拮抗剂，很少引起药物性超敏综合征（DIHS）。根据不良事件通用术语标准（CTCAE），一名患有前列腺癌和多发性骨转移的75岁男性患者在阿帕鲁胺联合GnRH拮抗剂治疗3周后出现2级皮疹和3级肝功能障碍，随后出现3天发烧。10天后，症状恶化为3级皮疹和4级肝功能障碍。他符合DIHS的五项诊断标准。停止激素治疗，给予强的松龙加静脉注射免疫球蛋白（IVIG）。2天内疲劳消退，第6天出现皮疹，第10天肝功能改善至2级。患者目前正在服用阿比特龙和GnRH拮抗剂，无不良事件。结论：本报告强调了由于DIHS的风险，使用阿帕鲁胺时谨慎和定期血液检查的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A Case of Drug-Induced Hypersensitivity Syndrome Caused by Apalutamide

查看原文本刊更多论文

A Case of Drug-Induced Hypersensitivity Syndrome Caused by Apalutamide

Introduction

Apalutamide, an androgen receptor antagonist for prostate cancer, rarely causes drug-induced hypersensitivity syndrome (DIHS).

Case Presentation

A 75-year-old male with prostate cancer and multiple bone metastases developed grade 2 rash and grade 3 liver dysfunction according to the Common Terminology Criteria for Adverse Events (CTCAE) 3 weeks after starting apalutamide with a GnRH antagonist, followed by a 3-day fever. Ten days later, symptoms worsened to grade 3 rash and grade 4 liver dysfunction. He met five diagnostic criteria for DIHS. Hormonal therapy was discontinued, and prednisolone plus intravenous immunoglobulin (IVIG) was administered. Fatigue resolved within 2 days, rash by day 6, and liver function improved to grade 2 by day 10. The patient is currently on abiraterone and a GnRH antagonist without adverse events.